SOURCE: BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp.

June 24, 2015 09:30 ET

BriaCell Therapeutics Begins Trading on the OTCQB (ANCCF) and Presents at a New York Biotech Investor Conference

VANCOUVER, BC--(Marketwired - June 24, 2015) - BriaCell Therapeutics Corp (TSX VENTURE: BCT) (OTCQB: ANCCF) ("BriaCell", the "Company", or "BCT"), a clinical stage cancer immunotherapy company, has been approved to begin trading today on the OTCQB® Marketplace in the United States under the symbol "ANCCF". The Company will continue to trade on the Toronto Stock Exchange Venture under the symbol "BCT".

"The OTCQB offers U.S. investors easier access to BriaCell as we expand our presence in the rapidly evolving field of immuno-oncology", said Joseph Wagner, Ph.D., President & CEO of BriaCell. "Trading on the OTCQB enables us to introduce the company to a broader range of investors and retail brokers in the US, at a time when our sector has emerged as one of the most promising in cancer therapy."

BriaCell also announces that Dr. Wagner will today begin non-deal marketing to select investors in New York City, including a presentation to investors at an invite-only investor event, the Summer Equities Pitch, which is sponsored by a family office investor group. BriaCell was one of four biotechs invited to this private conference and will present to a large audience of qualified investors.

ABOUT BRIACELL
BriaCell is a breast cancer immunotherapy biotechnology company. Immunotherapies have come to the forefront of the fight against cancer, because they harness the body's own immune system in recognizing and selectively destroying the cancer cells, sparing normal ones. Immunotherapies are believed to be a more targeted, less toxic approach to managing cancer. This approach is also more likely to prevent recurrence and is not expected to produce the serious side effects seen with chemotherapy.

The Company has demonstrated unique and unprecedented results, and is intent on building upon these results to further advance BriaVax™ through the FDA Clinical Trials in order to help cancer patients with no other options. The results of two FDA Phase I clinical trials have been encouraging in terms of both safety and efficacy in patients with advanced, stage-IV breast cancer. Most uniquely, BriaCell has achieved these results in patients who had prior failed available therapies including various kinds of chemotherapy. In some cases, the lifespan was five times longer expected. The results were targeted, with little to no side effects, and were achieved rapidly, with regression occurring within 6 weeks.

In one patient, cancer regressed in all sites to which the cancer had spread, including lesions in the breast, lung, and even brain. This result was the most unique finding, given that the brain is largely considered an untouchable site in terms of cancer regression. Again, results were seen rapidly and with little to no adverse side effects.

The Company is planning to advance its cancer immunotherapy technology in an FDA Phase I/II clinical trial with up to 24 breast cancer patients with advanced stages of solid tumors. The FDA-approved protocol has provision to allow testing the vaccine in selected patients with other cancers as well, including prostate, ovarian, pancreas, lung and bladder cancers among others. Although the focus of the Company is currently breast cancer, it recognizes that upon further proof of concept, its technology may be applicable to such other cancers as well. For further information, please refer to Company's website at www.BriaCell.com or its introductory video www.youtube.com/watch?v=el-yFF1uHoQ

The TSX Venture Exchange Inc. has in no way passed upon the merits of the Company has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors -- including the availability of funds, the results of financing efforts, the results of exploration activities -- that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States or elsewhere. These securities have not been, and will not be, registered in the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.

View Full Site

Image Available: http://www.marketwire.com/library/MwGo/2015/6/24/11G045729/Images/BriaCell_-_Highlights_-_One_Pager-1315789228665-783710512986.jpg

Embedded Video Available: https://www.youtube.com/watch?v=el-yFF1uHoQ

Attachment Available: http://www.marketwire.com/library/MwGo/2015/6/24/11G045729/BriaCell_-_Highlights-120191398917-274725590219.pdf

Contact Information

  • CONTACT INFORMATION
    For further information contact BriaCell Therapeutics Corp:

    Beverly Hills Cancer Center
    8900 Wilshire Blvd, 3rd Floor
    90211, Beverly Hills, CA

    Dr. Joseph Wagner
    President & CEO
    Phone: 1-888-485-6340
    Email: JWagner@BriaCell.com